Blaze Bioscience Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Mezzanine
- Latest Deal Amount
-
$8.06M
- Investors
-
6
Blaze Bioscience General Information
Description
Operator of a biotechnology company intended to improve the lives of cancer patients. The company leverages tumor paint technology to provide real-time, clear visualization of cancer cells throughout surgery to monitor cancer cells and distinguish tumors from healthy tissue, enabling surgeons to have precise and complete surgical removal of cancer and improved detection facility, sparing surrounding normal tissue.
Contact Information
Website
www.blazebioscience.comCorporate Office
- 530 Fairview Avenue North
- Suite 1400
- Seattle, WA 98109
- United States
Corporate Office
- 530 Fairview Avenue North
- Suite 1400
- Seattle, WA 98109
- United States
Blaze Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Mezzanine | 15-Feb-2024 | $8.06M | Completed | Generating Revenue | ||
| 12. Mezzanine | 06-Oct-2022 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Private | 21-Feb-2022 | Completed | Generating Revenue | |||
| 10. Mezzanine | 07-Oct-2021 | Completed | Generating Revenue | |||
| 9. Mezzanine | 30-Oct-2020 | Completed | Generating Revenue | |||
| 8. Debt - PPP | 01-May-2020 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B2) | 02-Apr-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series B1) | 03-Oct-2017 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC | 22-Apr-2016 | $19.6M | Completed | Clinical Trials - Phase 2 | ||
| 4. Grant | 19-Sep-2014 | $1.5M | $19.6M | Completed | Clinical Trials - Phase 1 |
Blaze Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series B | 12,500,000 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $0.84 | 11.96% |
| Series A | 11,656,259 | $0.000100 | 8% | $0.88 | $0.88 | 1x | $0.68 | 10.15% |
Blaze Bioscience Comparisons
Industry
Financing
Details
Blaze Bioscience Competitors (22)
One of Blaze Bioscience’s 22 competitors is GeneCast Biotechnology, a Private Equity-Backed company based in Wuxi, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | ||||
| Avelas Biosciences | Venture Capital-Backed | San Diego, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| OncoResponse | Venture Capital-Backed | Houston, TX | ||||
| Lumicell | Venture Capital-Backed | Newton, MA |
Blaze Bioscience Patents
Blaze Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026102332-A1 | Nerve and tumor homing agents and methods of use thereof | Pending | 08-Nov-2024 | ||
| WO-2024249812-A2 | Egf variants and methods of use thereof | Inactive | 01-Jun-2023 | ||
| WO-2024249812-A3 | Egf variants and methods of use thereof | Inactive | 01-Jun-2023 | ||
| AU-2023303521-A1 | Engineered liquid crystal shutter as a dynamic long-pass optical filter | Pending | 08-Jul-2022 | ||
| EP-4551988-A2 | Engineered liquid crystal shutter as a dynamic long-pass optical filter | Pending | 08-Jul-2022 | G02F1/13306 |
Blaze Bioscience Signals
Blaze Bioscience Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| W Venture Capital | Venture Capital | Minority | ||
| B Cubed Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| W&W Capital | Venture Capital | Minority | ||
| Keiretsu Capital | Venture Capital | Minority |
Blaze Bioscience Acquisitions (1)
Blaze Bioscience’s most recent deal was a Merger/Acquisition with Teal Light Surgical.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Teal Light Surgical | Merger/Acquisition | Diagnostic Equipment |
Blaze Bioscience FAQs
-
When was Blaze Bioscience founded?
Blaze Bioscience was founded in 2010.
-
Where is Blaze Bioscience headquartered?
Blaze Bioscience is headquartered in Seattle, WA.
-
What is the size of Blaze Bioscience?
Blaze Bioscience has 12 total employees.
-
What industry is Blaze Bioscience in?
Blaze Bioscience’s primary industry is Biotechnology.
-
Is Blaze Bioscience a private or public company?
Blaze Bioscience is a Private company.
-
What is Blaze Bioscience’s current revenue?
The current revenue for Blaze Bioscience is .
-
How much funding has Blaze Bioscience raised over time?
Blaze Bioscience has raised $117M.
-
Who are Blaze Bioscience’s investors?
W Venture Capital, B Cubed Ventures, , W&W Capital, and Keiretsu Capital are 5 of 6 investors who have invested in Blaze Bioscience.
-
Who are Blaze Bioscience’s competitors?
GeneCast Biotechnology, Avelas Biosciences, Inovio Pharmaceuticals, OncoResponse, and Lumicell are some of the 22 competitors of Blaze Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process